Skip to main content

Table 2 List of METTL3 modulators

From: N6-methyladenosine methyltransferases: functions, regulation, and clinical potential

Type

Function

Name/Company

IC50/EC50

Cancer

Estimated phase I trial start date

References

Activator

Specific activator

Compound 3

117 nM

ND

ND

[121]

Inhibitor

Pan-MTase inhibitor

Sinefungin

2.36μΜ

ND

ND

[121]

3-deazaadenosine

ND

ND

ND

[129]

Specific inhibitor

Compound 2

8.7 μM

ND

ND

[126]

UZH1a

280 nM

AML

ND

[127]

STM2457/STORM Therapeutics

16.9 nM

AML

2021

[128]

Accent Therapeutics

ND

AML, NSCLC

2021, 2022

[120]

  1. AML acute myeloid leukemia, NSCLC non-small cell lung cancer, ND no data available